Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 9,551 shares, a drop of 83.7% from the July 15th total of 58,489 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 481,032 shares, the short-interest ratio is currently 0.0 days.

Oncotelic Therapeutics Stock Performance

OTLC stock traded up $0.02 on Thursday, reaching $0.05. 490,725 shares of the company were exchanged, compared to its average volume of 282,098. The firm has a market capitalization of $22.23 million, a PE ratio of 0.08 and a beta of -0.23. Oncotelic Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.11. The stock’s fifty day moving average price is $0.04 and its 200 day moving average price is $0.05. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.11 and a quick ratio of 0.11.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.